Topiramate for migraine prophylaxis: Addressing the blood- brain barrier-related pharmacokinetic-pathophysiological disconnect [1]

International Journal of Clinical Practice

Volumn 60, Issue 3, 2006, Pages 367-368

  Gupta, V K ^a  

^a Dubai eGovernment Dubai Police   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; ATENOLOL; BOTULINUM TOXIN; GLYCERYL TRINITRATE; LAMOTRIGINE; MAGNESIUM; NADOLOL; NIFEDIPINE; NIMODIPINE; PROPRANOLOL; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

BLOOD BRAIN BARRIER; CHANNEL GATING; CLINICAL TRIAL; CLUSTER HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG RESPONSE; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; HEART ATRIUM SEPTUM DEFECT; HUMAN; LETTER; MIGRAINE; MIGRAINE AURA; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROMODULATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; SEIZURE; TENSION HEADACHE;

BLOOD-BRAIN BARRIER; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 33644770231     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.0796a.x     Document Type: Letter

References (16)

1. Bussone G, Diener H-C, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005; 59: 961-8.
2. Lampl C, Bonelli S, Ransmayr G. Efficacy of topiramate in migraine aura prophylaxis. preliminary results of 12 patients. Headache 2004; 44: 174-6.
3. Láinez MJA, Pascual J, Pascual AM, Santonja JM, Ponz A, Salvador A. Topiramate in the prophylactic treatment of cluster headache. Headache 2003; 43: 784-9.
4. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109-12.
5. Spacey SD, Hildebrand ME, Materek LA, Bird TD, Snutch TP. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann Neurol 2004; 56: 213-20.
6. Murphy VA, Johanson CE. Acidosis, acetazolamide, and amiloride: Effects on 22Na transfer across the blood-brain and blood-CSF barriers. J Neurochem 1989; 52: 1058-63.
7. Gupta VK. Magnesium therapy for migraine: Do we need more trials or more reflection? Headache 2004; 44: 445-6.
8. Gupta VK. Non-lateralizing brain PET changes in migraine: Phenomenology versus pharmacology? Brain 2004; 127: E12.
9. Gupta VK. Migraine, cortical excitability and evoked potentials: A clinico-pharmacological perspective. Brain 2005; 128: E36.
10. Silberstein SD, Young WB. Migraine aura and prodrome. Semin Neurol 1995; 15: 175 82.
11. Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 2003; 56: 213-20.
12. Gupta VK. Management of migraine aura: Basic theoretical and clinical reconsiderations. Headache 2005 (in press).
13. Gupta VK. Migraine, epilepsy, and brain neuronal hyperexcitation. Headache 2005; 45: 89.
14. Bonuso S, Marano E, Stasio ED, Sorge F, Barbieri F, Ullucci E. Source of pain and primitive dysfunction in migraine: An identical site? J Neurol Neurosurg Psychiatry 1989; 52: 1351-4.
15. Gupta VK. ASD closure for migraine: Is there a scientific basis? Eur Heart J 2005; 26: 1446.
16. Gupta VK. Botulinum toxin for treatment of migraine: Randomized controlled trials versus basic sciences. J Neurol Neurosurg Psychiatry 2004 (Published online 12 July 2004). Available at: http://www.jnnp.bmjjournals.com/cgi/eletters/75/7/951#212